First-line gefitinib (IRESSA) versus vinorelbine (invite): A randomized phase II study in elderly patients with advanced non-small-cell lung cancer

被引：0
|
作者：
Crino, L.
Zatlouka, P.
Reck, M.
Pesek, M.
Thompson, J. C.
Forc, H. E. R.
Ghiorghiu, S.
Duffield, E. L.
Armour, A.
Cullen, M.
机构：
[1] Perugia Hosp, Perugia, Italy
[2] Fac Hosp Bulovka, Prague, Czech Republic
[3] Hosp Grosshansdorf, Grosshansdorf, Germany
[4] Fac Hosp, Plzen, Czech Republic
[5] Birmingham Heart England Hosp, Birmingham, W Midlands, England
[6] Cambridge Univ Hosp NHS Trust, Cambridge, England
[7] AstraZeneca, Macclesfield, Cheshire, England
[8] Univ Hosp Birmingham, Birmingham, W Midlands, England
来源：
ANNALS OF ONCOLOGY | 2007年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：21 / 22
页数：2
相关论文
共 50 条
  • [1] Gefitinib (IRESSA) versus vinorelbine in chemonaive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized Phase II study
    Crino, Lucio
    Zatloukal, Petr
    Reck, Martin
    Pesek, Milos
    Thomson, Joyce
    Ford, Hugo
    Hirsch, Fred
    Duffield, Emma
    Armour, Alison
    Cullen, Michael
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S341 - S341
  • [2] Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE):: A randomized, phase II study
    Crino, Lucio
    Cappuzzo, Federico
    Zatloukal, Petr
    Reck, Martin
    Pesek, Milos
    Thompson, Joyce C.
    Ford, Hugo E. R.
    Hirsch, Fred R.
    Varella-Garcia, Marileila
    Ghiorghiu, Serban
    Duffield, Emma L.
    Armour, Alison A.
    Speake, Georgina
    Cullen, Michael
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (26) : 4253 - 4260
  • [3] First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: A phase II study
    Niho, S
    Kubota, K
    Goto, K
    Yoh, K
    Ohmatsu, H
    Kakinuma, R
    Saijo, N
    Nishiwaki, Y
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (01) : 64 - 69
  • [4] Gefitinib(Iressa) as first-line therapy in advanced non-small lung cancer
    Zimmermann, M
    Luthi, F
    Zouhair, A
    Bauer, J
    Leyvraz, S
    Stupp, R
    [J]. LUNG CANCER, 2005, 49 : S276 - S276
  • [5] Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer
    Argiris, A
    Mittal, N
    [J]. LUNG CANCER, 2004, 43 (03) : 317 - 322
  • [6] First-Line Single Agent Treatment With Gefitinib in Advanced Non-Small-Cell Lung Cancer Patients
    Yin, Yong-mei
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2009, 63 (05) : 325 - 325
  • [7] First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer
    Yin Y.-M.
    Geng Y.-T.
    Shao Y.-F.
    Hu X.-L.
    Li W.
    Shu Y.-Q.
    Wang Z.-X.
    [J]. Journal of Experimental & Clinical Cancer Research, 29 (1)
  • [8] Docetaxel Versus Vinorelbine in Elderly Patients With Advanced Non-Small-Cell Lung Cancer
    Karampeazis, Athanasios
    Georgoulias, Vassilis
    [J]. CLINICAL LUNG CANCER, 2012, 13 (05) : 397 - 397
  • [9] First-Line Dacomitinib versus Gefitinib in Advanced Non-Small-Cell Lung Cancer with EGFR Mutation Subgroups
    Wu, Y.
    Cheng, Y.
    Zhou, X.
    Lee, K. H.
    Nakagawa, K.
    Niho, S.
    Tsuji, F.
    Rosell, R.
    Corral, J.
    Migliorino, M. R.
    Pluzanski, A.
    Linke, R.
    Sbar, E.
    Wang, T.
    Zhang, H.
    Mok, T.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1754 - S1754
  • [10] Phase I/II study of gemcitabine plus vinorelbine as first-line chemotherapy of non-small-cell lung cancer
    Lorusso, V
    Carpagnano, F
    Frasci, G
    Panza, N
    Di Rienzo, G
    Cisternino, ML
    Napoli, G
    Orlando, S
    Cinieri, S
    Brunetti, C
    Palazzo, S
    De Lena, M
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (02) : 405 - 411
12345